Compoundlive

Organism list not requested in this search
BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 31.4 MICROMOLS/ACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN CYP1A2.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONCENTRATION VARIABLE NOT STATED ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30201 * PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED NOT STATED ACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN P450 CYP1A2-METABOLISM OF AFB1.
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10.0N MOL/INACTIVE * L04448 * VS.HUMAN ENDOMETRIAL CELLS, ISHIKAWA VAR I.
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONCENTRATION VARIABLE NOT STATED ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30229 * IN HUMAN FETAL OSTEOBLAST CELL LINE HFOB/ER PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 5.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30198 * VS.KS-IMM CELLS.
PHARMACOLOGY OF COMPOUND - IN VITRO * AGAR PLATE * MIC 12.5 MCG/ML * ACTIVE * STREPTOCOCCUS SPECIES * L26307 * BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONCENTRATION VARIABLE NOT STATED ACTIVE * EIMARIA MAXIMA * SEE ARTICLE FOR OTHER TEST RESULTS. * L30197 * PHARMACOLOGY OF COMPOUND - IN VIVO * IN RATION * CHICKEN * CONC USED 20.0 PPM/ACTIVE * EIMERIA TENELLA * L30197 * PHARMACOLOGY OF COMPOUND - IN VIVO * IN RATION * CHICKEN * CONC USED 20.0 PPM/ACTIVE * EIMARIA MAXIMA * L30197 * PHARMACOLOGY OF COMPOUND - IN VIVO * IN RATION * CHICKEN * CONC USED 20.0 PPM/ACTIVE * EIMERIA ACERVULINA * L30197 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 5.0 MICROMOLS/ACTIVE * HEPATOCYTES * L15429 * VS.TBH-INDUCED CYTOTOXICITY.
PHARMACOLOGY OF COMPOUND - IN VIVO * IN RATION * MOUSE * DOSE 1.0 % OF DIET/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30228 * VS. PLASMA AND HEPATIC TRIGLYCERIDE LEVELS. 31 DAYS DOSING PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 5.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30199 * VS. MCF-7 AND T47-D BREAST CANCER CELL LINES.
PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 1.0 MCG/ML * ACTIVE * PLASMODIUM FALCIPARUM * L25890 * PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 8.2 MICROMOLS/ACTIVE * PLASMODIUM FALCIPARUM * SEE ARTICLE FOR OTHER TEST RESULTS. * L30185 * BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 2.0 MICROMOLS/ACTIVE * L27371 * 48% INHIBITION INDUCED B IQ.
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 0.1 MILLIMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30335 * VS. SEVERAL MUTAGENIC CHALLENGES IN HEP-G-2-CELLS.
PHARMACOLOGY OF COMPOUND - IN VITRO * AGAR PLATE * CONCENTRATION NOT GIVEN NOT STATED ACTIVE * SALMONELLA TYPHIMURIUM TA98 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30636 * PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * L10217 * VS.TBARS FORMATION IN LDL.
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 5.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27366 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 5.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27366 * PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 0.1 MG/ML * WEAK ACTIVITY * SEE ARTICLE FOR OTHER TEST RESULTS. * L27368 * VS.LIPID PEROXIDATION INDUCED BY SIN-1 IN LDL. 24% INHIBITION.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/WEAK ACTIVITY * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS. DPPH ASSAY PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.2 MICROMOLS/ACTIVE * VS.INHIBITION OF 1-1-DIPHENYL-2-PICRYLHYDRAZYL RADICAL FORMATION. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.2 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 30.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30335 * VS. DPPH ASSAY.
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 3.47 MICROMOLS/ACTIVE * CA-MAMMARY-MCF-7 * L03979 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED NOT STATED INACTIVE * HUMAN COLON CANCER CELL LINE HT29 * L03979 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 0.52 MICROMOLS/ACTIVE * CA-HUMAN-OVARIAN A2780 * L03979 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29422 * USING MTT ASSAY IN BENIGN PROSTATIC HYPERPLASIA AND ANDROGEN INDEPENDENT PROSTATE CANCER CELL LINES PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 13.2 MICROMOLS/ACTIVE * CA-PC3(PROSTATE) * L30466 * PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 12.3 MICROMOLS/CA-HUMAN-PROSTATE-DU 145 * L30466 * BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 1.7 MCG/ML * ACTIVE * VIRUS-BOVINE VIRAL DIARRHEA(BVDV) * L25902 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 2.5 MCG/ML * ACTIVE * VIRUS-CYTOMEGALOVIRUS * L25902 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 2.7 MCG/ML * ACTIVE * VIRUS-HERPES SIMPLEX 1 * L25902 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 1.5 MCG/ML * ACTIVE * VIRUS-HERPES SIMPLEX 2 * L25902 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED NOT STATED INACTIVE * VIRUS-RHINOVIRUS * L25902 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 0.82 MCG/ML * ACTIVE * VIRUS-HIV-1 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30188 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 1.0 MCG/ML * ACTIVE * LEUK-HL60 * DATA INCOMPLETE - DERIVED FROM AN ABSTRACT. * L19788 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 2.6 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L26906 * VS.40-16 HUMAN COLON CANCER CELLS.
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29422 * USING ANNEXIN V ASSAY IN HUMAN BENIGN PROSTATIC HYPERPLASIA (BPH-1) EPITHELIAL AND ANDROGEN INDEPENDENT PROSTATE CANCER CELL LINES BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 75.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30201 * VS.3T3-L-1 FIBROBLASTS.
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 3.2 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30162 * VS. BREAST CANCER CELLS SK-BR-3 PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 20.3 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30195 * VS.JAR CELLS.
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONCENTRATION VARIABLE NOT STATED ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30191 * BINDING TO CYTOSOLIC PROTEINS IN CACO-2 CELLS MAY CONTRIBUTE TO THE POOR BIOAVAILABILITY OF XANTHOHUMOL.
PHARMACOLOGY OF COMPOUND - IN VITRO * NOT STATED ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30218 * USING AN ONLINE LC/MS SCREENING ASSAY BASED ON THE MASS SPECTROMETRIC IDENTIFICATION OF COMPOUNDS THAT ALKYLATE THE CYTOPLASMIC ACTIN-BINDING KEAP1 PROTEIN, LEADING TO THE UPREGULATION OF ANTIOXIDANT RESPONSE ELEMENT-MEDIATED INDUCTION OF PHASE II DETOXIFYING AND ANTIOXIDATIVE STRESS ENZYME NRF2 PHARMACOLOGY OF COMPOUND - IN VITRO * MOUSE * IC50 0.02 MICROMOLS/ACTIVE * VS.FORMALIN-INDUCED PEDAL EDEMA. * L30258 * VS. INCIDENCE OF DMBA-INDUCED LESIONS IN MOUSE MAMMARY ORGAN CULTURE PHARMACOLOGY OF COMPOUND - IN VITRO * MOUSE * IC50 0.02 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30258 * VS. INCIDENCE OF DMBA-INDUCED LESIONS IN MOUSE MAMMARY ORGAN CULTURE PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 200 MICROMOLS/INACTIVE * CA-HUMAN-PROSTATE PC-3 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30253 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONCENTRATION VARIABLE NOT STATED ACTIVE * CA-HUMAN-BREAST-MCF-7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30229 * BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/INACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN CYP2E1.
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 30.0 MCG/ML * ACTIVE * CELLS-HAMSTER-CHINESE-V79 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30229 * SEVEN DAY INCUBATION PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED NOT STATED ACTIVE * DATA INCOMPLETE - DERIVED FROM AN ABSTRACT. * L19788 * PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.2 MICROMOLS/ACTIVE * L27371 * VS.HUMAN CYP-1-A-2.
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10 MCG/ML * ACTIVE * CA-HEPATOCARCINOMA-G2 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30636 * VS. 2-AMINO-3-METHYLIMIDAZO[4,5-F] QUINOLINE INDUCED DNA DAMAGE PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 100.0 MICROMOLS/WEAK ACTIVITY * CA-MAMMARY-MCF-7 * L03979 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 100.0 MICROMOLS/WEAK ACTIVITY * HUMAN COLON CANCER CELL LINE HT29 * L03979 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 100.0 MICROMOLS/WEAK ACTIVITY * CA-HUMAN-OVARIAN A2780 * L03979 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 24.4 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L26907 * VS.B-CHRONIC LYMPHOCYTIC LEUKEMIA CELLS.
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 30.7 MICROMOLS/EQUIVOCAL * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 200 MICROMOLS/ACTIVE * HUMAN PROSTATE CANCER CELL LINE DU-145 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30253 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 200 MICROMOLS/ACTIVE * CA-HUMAN-PROSTATE PC-3 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30253 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10 MCG/ML * EQUIVOCAL * CA-HEPATOCARCINOMA-G2 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30636 * DIACYLGLYCEROL ACYLTRANSFERASE INHIBITION PHARMACOLOGY OF COMPOUND - IN VITRO * RAT * IC50 50.3 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * H20962 * DIACYLGLYCEROL ACYLTRANSFERASE INHIBITION PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 21.2 MICROMOLS/ACTIVE * CELLS-RAJI * H20962 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 100.0 MCG/ML * WEAK ACTIVITY * LEUK-HL60 * DATA INCOMPLETE - DERIVED FROM AN ABSTRACT. * L19788 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 23.0 MICROMOLS/ACTIVE * HUMAN BREAST CANCER CELL LINE MDA-MB-435 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30258 * BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 0.5 MICROMOLS/ACTIVE * CA-MAMMARY-MCF-7 * L03979 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 0.022 MICROMOLS/ACTIVE * HEPATOMA-H4IIEC3/G * SEE ARTICLE FOR OTHER TEST RESULTS. * L30258 * VS INHIBITION OF CYP1A, A PHASE I (CONJUGATING) ENZYME PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED NOT STATED INACTIVE * L14681 * IN ISHIKAWA CELLS.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONCENTRATION VARIABLE NOT STATED INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27370 * VS. ER-ALPHA AND ER-BETA.
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10.0 MCG/ML * ACTIVE * OSTEOSARCOMA-U-2 OS * SEE ARTICLE FOR OTHER TEST RESULTS. * L30229 * VS. REGULATION OF ESTROGEN-INDUCIBLE GENE EXPRESSION PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L10219 * VS.HUMAN P450 CYP1B1 AND HUMAN P450 CYP1A1.
PHARMACOLOGY OF COMPOUND - IN VIVO * INTRAGASTRIC * RAT * DOSE 100.0 MG/KG * INACTIVE * L26909 * PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 75.0 NANOMOLS/ACTIVE * NEURON * L30576 * IN HIPPOCAMPAL N EURONS.
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 75.0 NANOMOLS/STRONG ACTIVITY * CELLS-HIPPOCAMPAL NEURON * SEE ARTICLE FOR OTHER TEST RESULTS. * L30230 * BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 0.001 MICROMOLS/ACTIVE * LIVER * L30577 * VS-IQ AND BAP-INDUCED DNA DAMAGE.
PHARMACOLOGY OF COMPOUND - IN VIVO * SC * MOUSE * DOSE 5.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30198 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONCENTRATION VARIABLE NOT STATED ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27089 * IN RAT THYROID-DERIVED FRTL-5 CELLS PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * L10217 * VS.CONJUGATED DIENE FORMATION IN LDL.
PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 6.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.FERROUS SULFATE INDUCED LIPID PEROXIDATION.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.FE3+-ADP/NADPH INDUCED LIPID PEROXIDATION.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.TERT-BUTYL HYDROPEROXIDE INDUCED LIPID PEROXIDATION.
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED NOT STATED ACTIVE * L08929 * METABOLISM TO ISOXANTHOHUMOL.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED VAR ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L26905 * THE STUDY SUGGESTED A PROMINENT ROLE FOR THE GLUCURONIDATION AND SULFATION OF XN IN THE LIVER AS WELL AS IN THE GASTROINTESTINAL TRACT.
BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VIVO * INTRAGASTRIC * RAT * DOSE 1000 MG/KG * ACTIVE * L27032 * 16 METABOLITES AND 6 PREVIOUSLY KNOWN METABOLITES WERE ISLOATED.
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONCENTRATION VARIABLE NOT STATED ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27365 * METABOLIZED TO TWO MAJOR GLUCURONIDES BY RAT AND HUMAN MICROSOMES PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONCENTRATION VARIABLE NOT STATED ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27367 * CONVERSION TO CHALCONE DERIVATIVES BY RAT LIVER MICROSOMES.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONCENTRATION VARIABLE NOT STATED ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29205 * METABOLIZED TO ISOXANTHOHUMOL.
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10.0 MICROMOLS/ACTIVE * CA-HEPATOCARCINOMA-G2 * L30228 * VS. ACTIVATION OF FARNESOID RECEPTOR X AND MODULATION OF GENES INVOLVED IN LIPID AND GLUCOSE METABOLISM PHARMACOLOGY OF COMPOUND - IN VIVO * INTRAGASTRIC * RAT * DOSE 100.0 MG/KG * INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L26908 * VS.COMPOSITION OF INTESTINAL MICROBIOTA.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/INACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN P450 CYP1A2-METABOLISM OF AFB1.
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 5.0 MCG/ML * ACTIVE * MACROPHAGE CELL LINE RAW 264.7 * H31111 * VS.LPS/INF-GAMMA INDUCED NO.
PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 8.3 MICROMOLS/ACTIVE * MACROPHAGE CELL LINE RAW 264.7 * H32723 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29422 * IN HUMAN BENIGN PROSTATIC HYPERPLASIA EPITHELIAL (BPH-1) CELLS BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 1.7 MICROMOLS/ACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30258 * CONCENTRATION REQUIRED TO DOUBLE QUINONE REDUCTASE ACTIVITY PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CD50 2.1 MICROMOLS/ACTIVE * L27369 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 1.7 MICROMOLS/ACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 2.0 MCG/ML * ACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30218 * ASSAY USED TO DETERMINE THE CONCENTRATION REQUIRED TO DOUBLE QUINONE REDUCTASE ACTIVITY.
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * ED50 1.7 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 1.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30258 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 1.28 MCG/ML * ACTIVE * VIRUS-HIV-1 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30188 * BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VIVO * INTRAGASTRIC * RAT * DOSE 1000 MG/KG * ACTIVE * L26909 * XANTHOHUMOL B (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.DPPH ASSAY PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * VS.INHIBITION OF 1-1-DIPHENYL-2-PICRYLHYDRAZYL RADICAL FORMATION. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.HEP-C-2-ARE-C-8 CELLS PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * THE CORRECT IDENTIFICATION OF THIS PLANT IS HIGHLY QUESTIONABLE. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * DIACYLGLYCEROL ACYLTRANSFERASE INHIBITION PHARMACOLOGY OF COMPOUND - IN VITRO * RAT * IC50 194.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * H20962 * DIACYLGLYCEROL ACYLTRANSFERASE INHIBITION PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 33.8 MICROMOLS/ACTIVE * CELLS-RAJI * H20962 * BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL B (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 1.0 MCG/ML * ACTIVE * MACROPHAGE CELL LINE RAW 264.7 * H31111 * VS.LPS/INF-GAMMA INDUCED NO.
PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 5.6 MICROMOLS/ACTIVE * MACROPHAGE CELL LINE RAW 264.7 * H32723 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 4.5 MICROMOLS/WEAK ACTIVITY * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * ED50 4.5 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * XANTHOHUMOL B,DEMETHYL: (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/WEAK ACTIVITY * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.DPPH ASSAY PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * VS.INHIBITION OF 1-1-DIPHENYL-2-PICRYLHYDRAZYL RADICAL FORMATION. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.HEP-G-2-ARE-C-8 CELLS PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * THE CORRECT IDENTIFICATION OF THIS PLANT IS HIGHLY QUESTIONABLE. * L30193 * BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL B,DEMETHYL: (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * ED50 2.7 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * XANTHOHUMOL C (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.DPPH ASSAY PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * VS.INHIBITION OF 1-1-DIPHENYL-2-PICRYLHYDRAZYL RADICAL FORMATION. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.HEP-G-2-ARE-C-8 CELLS PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * THE CORRECT IDENTIFICATION OF THIS PLANT IS HIGHLY QUESTIONABLE. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 4.8 MICROMOLS/WEAK ACTIVITY * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL C (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * ED50 4.8 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * XANTHOHUMOL D (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/WEAK ACTIVITY * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.DPPH ASSAY PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * VS.INHIBITION OF 1-1-DIPHENYL-2-PICRYLHYDRAZYL RADICAL FORMATION. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * NOT STATED ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30218 * USING AN ONLINE LC/MS SCREENING ASSAY BASED ON THE MASS SPECTROMETRIC IDENTIFICATION OF COMPOUNDS THAT ALKYLATE THE CYTOPLASMIC ACTIN-BINDING KEAP1 PROTEIN, LEADING TO THE UPREGULATION OF ANTIOXIDANT RESPONSE ELEMENT-MEDIATED INDUCTION OF PHASE II DETOXIFYING AND ANTIOXIDATIVE STRESS ENZYME NRF2 PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.HEP-G-2-ARE-C-8 CELLS PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * THE CORRECT IDENTIFICATION OF THIS PLANT IS HIGHLY QUESTIONABLE. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 5.0 MCG/ML * ACTIVE * MACROPHAGE CELL LINE RAW 264.7 * H31111 * VS.LPS/INF-GAMMA INDUCED NO.
BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL D (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 9.4 MICROMOLS/ACTIVE * MACROPHAGE CELL LINE RAW 264.7 * H32723 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 7.8 MICROMOLS/WEAK ACTIVITY * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * ED50 7.4 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * XANTHOHUMOL G (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.DPPH ASSAY PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * VS.INHIBITION OF 1-1-DIPHENYL-2-PICRYLHYDRAZYL RADICAL FORMATION. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.HEP-G-2-ARE-C-8 CELLS PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * THE CORRECT IDENTIFICATION OF THIS PLANT IS HIGHLY QUESTIONABLE. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL G (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * ED50 4.5 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * XANTHOHUMOL H (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.DPPH ASSAY PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * VS.INHIBITION OF 1-1-DIPHENYL-2-PICRYLHYDRAZYL RADICAL FORMATION. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.HEP-G-2-ARE-C-8 CELLS PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * THE CORRECT IDENTIFICATION OF THIS PLANT IS HIGHLY QUESTIONABLE. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 7.1 MICROMOLS/WEAK ACTIVITY * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * ED50 7.1 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL I (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.DPPH ASSAY PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * VS.INHIBITION OF 1-1-DIPHENYL-2-PICRYLHYDRAZYL RADICAL FORMATION. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.HEP-G-2-ARE-C-8 CELLS PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * THE CORRECT IDENTIFICATION OF THIS PLANT IS HIGHLY QUESTIONABLE. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED >30.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * ED50 >20.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * XANTHOHUMOL J,DEMETHYL: (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/WEAK ACTIVITY * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.DPPH ASSAY BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL J,DEMETHYL: (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * VS.INHIBITION OF 1-1-DIPHENYL-2-PICRYLHYDRAZYL RADICAL FORMATION. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.HEP-G-2-ARE-C-8 CELLS PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * THE CORRECT IDENTIFICATION OF THIS PLANT IS HIGHLY QUESTIONABLE. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 7.8 MICROMOLS/ACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * ED50 7.8 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * XANTHOHUMOL K,1''-2''-DIHYDROXY (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.DPPH ASSAY PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.HEP-G-2-ARE-C-8 CELLS BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL K,1''-2''-DIHYDROXY (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * ED50 2.5 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * XANTHOHUMOL,2''-3''-DIHYDRO: (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 12.9 MICROMOLS/ACTIVE * PLASMODIUM FALCIPARUM * SEE ARTICLE FOR OTHER TEST RESULTS. * L30185 * XANTHOHUMOL,4'-O-5'-C-DIPRENYL: (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 0.1 MG/ML * ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27368 * VS.LIPID PEROXIDATION INDUCED BY SIN-1 IN LDL. 88% INHIBITION.
XANTHOHUMOL,4'-O-5'-DIPRENYL: (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.FERROUS SULFATE INDUCED LIPID PEROXIDATION.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 25.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.FE3+-ADP/NADPH INDUCED LIPID PEROXIDATION.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.TERT-BUTYL HYDROPEROXIDE INDUCED LIPID PEROXIDATION.
XANTHOHUMOL,4'-O-5'-DIPRENYL; (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 5.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27366 * BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL,4'-O-METHYL: (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * L10217 * VS.TBARS FORMATION IN LDL.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 0.1 MG/ML * ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27368 * VS.LIPID PEROXIDATION INDUCED BY SIN-1 IN LDL. 51% INHIBITION.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 25.0 MICROMOLS/ACTIVE * L10217 * VS.CONJUGATED DIENE FORMATION IN LDL.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.FERROUS SULFATE INDUCED LIPID PEROXIDATION.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.FE3+-ADP/NADPH INDUCED LIPID PEROXIDATION.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.TERT-BUTYL HYDROPEROXIDE INDUCED LIPID PEROXIDATION.
XANTHOHUMOL,4'-O-METHYL; (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 5.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27366 * XANTHOHUMOL,5'-PRENYL: (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/ACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN CYP1A2.
BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL,5'-PRENYL: (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10.0 MICROMOLS/ACTIVE * HEPATOCYTES * L15429 * VS.TBH-INDUCED CYTOTOXICITY.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * L10217 * VS.TBARS FORMATION IN LDL.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 0.1 MG/ML * WEAK ACTIVITY * SEE ARTICLE FOR OTHER TEST RESULTS. * L27368 * VS.LIPID PEROXIDATION INDUCED BY SIN-1 IN LDL. 31% INHIBITION.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/INACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN CYP2E1.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/ACTIVE * L10219 * VS.HUMAN P450 CYP1B1 AND HUMAN P450 CYP1A1.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/INACTIVE * L10217 * VS.CONJUGATED DIENE FORMATION IN LDL.
PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.FERROUS SULFATE INDUCED LIPID PEROXIDATION.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.FE3+-ADP/NADPH INDUCED LIPID PEROXIDATION.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.TERT-BUTYL HYDROPEROXIDE INDUCED LIPID PEROXIDATION.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/INACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN P450 CYP1A2-METABOLISM OF AFB1.
BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL,5'-PRENYL; (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 5.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27366 * XANTHOHUMOL,5''-TRANS-HYDROXY: (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.HEP-G-2-ARE-C-8 CELLS PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * THE CORRECT IDENTIFICATION OF THIS PLANT IS HIGHLY QUESTIONABLE. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10.2 MICROMOLS/WEAK ACTIVITY * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * ED50 10.2 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * XANTHOHUMOL,6-8-DIPRENYL: (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * VS.INHIBITION OF 1-1-DIPHENYL-2-PICRYLHYDRAZYL RADICAL FORMATION. * L30193 * BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL,6-8-DIPRENYL: (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * THE CORRECT IDENTIFICATION OF THIS PLANT IS HIGHLY QUESTIONABLE. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 5.1 MICROMOLS/WEAK ACTIVITY * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * XANTHOHUMOL,6'-DEMETHYL: (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 42.4 MICROMOLS/WEAK ACTIVITY * PLASMODIUM FALCIPARUM * SEE ARTICLE FOR OTHER TEST RESULTS. * L30185 * XANTHOHUMOL,DEMETHYL: (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10.0 MICROMOLS/INACTIVE * HEPATOCYTES * L15429 * VS.TBH-INDUCED CYTOTOXICITY.
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 100.0 MICROMOLS/WEAK ACTIVITY * SEE ARTICLE FOR OTHER TEST RESULTS. * L30184 * VS.BJAB CELLS.
PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 49.9 MICROMOLS/ACTIVE * CA-PC3(PROSTATE) * L30466 * PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 53.8 MICROMOLS/ACTIVE * CA-HUMAN-PROSTATE-DU 145 * L30466 * BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL,DEMETHYL: (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 100.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30184 * VS.BJAB CELLS.
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 50.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30184 * VS.BJAB CELLS.
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 100.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30184 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED NOT STATED INACTIVE * L14681 * IN ISHIKAWA CELLS.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.FERROUS SULFATE INDUCED LIPID PEROXIDATION.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.FE3+-ADP/NADPH INDUCED LIPID PEROXIDATION.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.TERT-BUTYL HYDROPEROXIDE INDUCED LIPID PEROXIDATION.
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CD50 7.5 MICROMOLS/ACTIVE * L27369 * XANTHOHUMOL,DEMETHYL; (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 5.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27366 * BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL,DIHYDRO: (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 23.0 MICROMOLS/ACTIVE * MACROPHAGE CELL LINE RAW 264.7 * H32723 * XANTHOHUMOL,DIHYDROXY: (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10.0 MCG/ML * ACTIVE * MACROPHAGE CELL LINE RAW 264.7 * H31111 * VS.LPS/INF-GAMMA INDUCED NO.
XANTHOHUMOL,DIPRENYL: (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.HEP-G-2-ARE-C-8 CELLS PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * ED50 5.1 MICROMOLS/ACTIVE * L29296 * XANTHOHUMOL,ISO: (FLAVANONE)
PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 4.5 MICROMOLS/ACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN CYP1A2.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONCENTRATION VARIABLE NOT STATED ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30201 * PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 25.0 MICROMOLS/ACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN P450 CYP1A2-METABOLISM OF AFB1.
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONCENTRATION VARIABLE NOT STATED ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30229 * IN HUMAN FETAL OSTEOBLAST CELL LINE HFOB/ER PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 2.0 MICROMOLS/NOT POSSIBLE TO INTERPRET RESULTS * L27371 * 84% INHIBITION INDUCED BY IQ.
BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL,ISO: (FLAVANONE)
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 25.0 MICROMOLS/ACTIVE * L10217 * VS.TBARS FORMATION IN LDL.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 0.1 MG/ML * ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27368 * VS.LIPID PEROXIDATION INDUCED BY SIN-1 IN LDL. 100% INHIBITION.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/WEAK ACTIVITY * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.DPPH ASSAY PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * VS.INHIBITION OF 1-1-DIPHENYL-2-PICRYLHYDRAZYL RADICAL FORMATION. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 4.69 MICROMOLS/ACTIVE * CA-MAMMARY-MCF-7 * L03979 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED NOT STATED INACTIVE * HUMAN COLON CANCER CELL LINE HT29 * L03979 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED NOT STATED WEAK ACTIVITY * CA-HUMAN-OVARIAN A2780 * L03979 * PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 45.2 MICROMOLS/ACTIVE * CA-PC3(PROSTATE) * L30466 * PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 47.4 MICROMOLS/ACTIVE * CA-HUMAN-PROSTATE-DU 145 * L30466 * BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL,ISO: (FLAVANONE)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED NOT STATED INACTIVE * VIRUS-BOVINE VIRAL DIARRHEA(BVDV) * L25902 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 12.0 MCG/ML * ACTIVE * VIRUS-CYTOMEGALOVIRUS * L25902 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED NOT STATED INACTIVE * VIRUS-HERPES SIMPLEX 1 * L25902 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 17.0 MG/ML * ACTIVE * VIRUS-HERPES SIMPLEX 2 * L25902 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 6.6 MCG/ML * ACTIVE * VIRUS-RHINOVIRUS * L25902 * PHARMACOLOGY OF COMPOUND - IN VITRO * CONCENTRATION NOT GIVEN NOT STATED MICROMOLS/WEAK ACTIVITY * SEE ARTICLE FOR OTHER TEST RESULTS. * L30201 * VS.3T3-L-1 FIBROBLASTS.
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 25.4 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30162 * VS. BREAST CANCER CELLS SK-BR-3 BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL,ISO: (FLAVANONE)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 139.7 MICROMOLS/WEAK ACTIVITY * SEE ARTICLE FOR OTHER TEST RESULTS. * L30195 * VS.JAR CELLS.
PHARMACOLOGY OF COMPOUND - IN VITRO * NOT STATED INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30218 * USING AN ONLINE LC/MS SCREENING ASSAY BASED ON THE MASS SPECTROMETRIC IDENTIFICATION OF COMPOUNDS THAT ALKYLATE THE CYTOPLASMIC ACTIN-BINDING KEAP1 PROTEIN, LEADING TO THE UPREGULATION OF ANTIOXIDANT RESPONSE ELEMENT-MEDIATED INDUCTION OF PHASE II DETOXIFYING AND ANTIOXIDATIVE STRESS ENZYME NRF2 PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 200 MICROMOLS/INACTIVE * CA-HUMAN-PROSTATE PC-3 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30253 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONCENTRATION VARIABLE NOT STATED ACTIVE * CA-HUMAN-BREAST-MCF-7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30229 * PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/INACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN CYP2E1.
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 30.0 MCG/ML * ACTIVE * CELLS-HAMSTER-CHINESE-V79 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30229 * SEVEN DAY INCUBATION PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 >5.0 MILLIMOLS/INACTIVE * M12709 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10.0 MICROMOLS/ACTIVE * MICROSOMES-HUMAN-LIVER * SEE ARTICLE FOR OTHER TEST RESULTS. * L30215 * ONLINE LC/MS ASSAY USED TO DETERMINE KINETICS OF PRENYL OXIDATION OF XANTHOHUMOL IN A VARIETY OF P450 ENZYME ISOTYPES.
BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL,ISO: (FLAVANONE)
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/INACTIVE * L27371 * VS.HUMAN CYP-1-A-2.
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 100.0 MICROMOLS/WEAK ACTIVITY * CA-MAMMARY-MCF-7 * L03979 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 100.0 MICROMOLS/WEAK ACTIVITY * HUMAN COLON CANCER CELL LINE HT29 * L03979 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 100.0 MICROMOLS/WEAK ACTIVITY * CA-HUMAN-OVARIAN A2780 * L03979 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 30.7 MICROMOLS/WEAK ACTIVITY * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.HEP-G-2-ARE-C-8 CELLS PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 200 MICROMOLS/ACTIVE * HUMAN PROSTATE CANCER CELL LINE DU-145 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30253 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 200 MICROMOLS/ACTIVE * CA-HUMAN-PROSTATE PC-3 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30253 * XANTHOHUMOL,ISO: (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 100.0 MICROMOLS/INACTIVE * HUMAN BREAST CANCER CELL LINE MDA-MB-435 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30258 * BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL,ISO: (FLAVANONE)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 0.5 MICROMOLS/ACTIVE * CA-MAMMARY-MCF-7 * L03979 * XANTHOHUMOL,ISO: (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 0.3 MICROMOLS/ACTIVE * HEPATOMA-H4IIEC3/G * SEE ARTICLE FOR OTHER TEST RESULTS. * L30258 * VS INHIBITION OF CYP1A, A PHASE I (CONJUGATING) ENZYME XANTHOHUMOL,ISO: (FLAVANONE)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10.0 MCG/ML * ACTIVE * OSTEOSARCOMA-U-2 OS * SEE ARTICLE FOR OTHER TEST RESULTS. * L30229 * VS. REGULATION OF ESTROGEN-INDUCIBLE GENE EXPRESSION PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L10219 * VS.HUMAN P450 CYP1B1 AND HUMAN P450 CYP1A1.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/INACTIVE * L10217 * VS.CONJUGATED DIENE FORMATION IN LDL.
PHARMACOLOGY OF COMPOUND - IN HUMANS * ORAL * HUMAN ADULT * DOSE 5.59 MG/DAY * ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * E02273 * DAILY DOSING FOR FOUR DAYS (3 WOMEN) WITH CONVERSION TO 8-PRENYL NARINGENIN. THIS OCCURS IN THE DISTAL COLON.
PHARMACOLOGY OF COMPOUND - IN VITRO * AGAR PLATE * CONCENTRATION NOT GIVEN NOT STATED SEE ARTICLE FOR OTHER TEST RESULTS. * E02286 * STANDARDIZED EXTRACTS WERE INCUBATED WITH FECAL SLURRY FROM FEMALE HUMAN SUBJECTS (N=100) TO DETERMINE VARIATION IN METABOLIC PATTERNS AND BACTERIAL CONVERSION RATES.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONCENTRATION VARIABLE NOT STATED ACTIVE * L28323 * EUBACTERIUM LIMOSUM FROM FECAL FLORA METABOLIZED ISOXANTHOHUMOL TO 8-PRENARINGENIN IN 90% YIELD.
BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL,ISO: (FLAVANONE)
PHARMACOLOGY OF COMPOUND - IN VITRO * CONCENTRATION VARIABLE NOT STATED ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29205 * METABOLIZED TO HYDROXYLATION OF THE PRENYL GROUP.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/. * MICROSOMES-HUMAN-LIVER * L30574 * METABOLISM BY CYTOCHROME P450 ENZYME CYP1A2.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/INACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN P450 CYP1A2-METABOLISM OF AFB1.
XANTHOHUMOL,ISO: (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 6.5 MICROMOLS/ACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30258 * CONCENTRATION REQUIRED TO DOUBLE QUINONE REDUCTASE ACTIVITY XANTHOHUMOL,ISO: (FLAVANONE)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED >50.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 * PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED <50.0 MCG/ML * INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30218 * ASSAY USED TO DETERMINE THE CONCENTRATION REQUIRED TO DOUBLE QUINONE REDUCTASE ACTIVITY.
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * ED50 >50.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * XANTHOHUMOL,ISO: (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 1.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30258 * BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL,TETRAHYDRO: (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/ACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN CYP1A2.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * L10217 * VS.TBARS FORMATION IN LDL.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/INACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN CYP2E1.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/ACTIVE * L10219 * VS.HUMAN P450 CYP1B1 AND HUMAN P450 CYP1A1.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * L10217 * VS.CONJUGATED DIENE FORMATION IN LDL.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.FERROUS SULFATE INDUCED LIPID PEROXIDATION.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 25.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.FERROUS SULFATE INDUCED LIPID PEROXIDATION.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 25.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.FE3+-ADP/NADPH INDUCED LIPID PEROXIDATION.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.TERT-BUTYL HYDROPEROXIDE INDUCED LIPID PEROXIDATION.
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/INACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN P450 CYP1A2-METABOLISM OF AFB1.
BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%
XANTHOHUMOL,TETRAHYDROXY: (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 0.1 MG/ML * ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27368 * VS.LIPID PEROXIDATION INDUCED BY SIN-1 IN LDL. 92% INHIBITION.
XANTHOHUMOL,TETRAHYDROXY; (FLAVONOID)
PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 5.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27366 * LITERATURE CITED
THE PRENYLFLAVONOID ISOXANTHOHUMOL FROM HOPS (HUMULUS IUPULUS L.) IS ACTIVATED INTO THE POTENT PHYTOESTROGEN 8-PRENYLNARINGENIN IN VITRO AND IN THE HUMAN INTESTINE POSSEMIERS,S: BOLCA,S: GROOTAERT,C: HEYERICK,A: DECROSS,K: DHOOGE,W: DE KEUKELEIRE,D: RABOT,S: VERSTRAETE,W: VAN DE WIELE,T: J NUTR (2006) 136 pp. 1862-1867 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
GHENT UNIVERSITY LABO MICROBIAL ECOLOGY TECHNOLOGY FACULTY BIOSCIENCE ENGINEERING GENT B-9000 BELGIUM METABOLISM OF ISOFLAVONES, LIGNANS AND PRENYLFLAVONOIDS BY INTESTINAL BACTERIA: PRODUCER PHENOTYPING AND RELATION WITH INTESTINAL COMMUNITY POSSEMIERS,S: EECKHAUDT,E: DEPYPERE,H: VERSTRAETE,W FEMS MICROBIAL ECOL (2007) 61 (2) pp. 372-383 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
GHENT UNIV LAB MICROBIAL ECOLOGY & TECHNOL GHENT BELGIUM XANTHOHUMOLS, DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS, FROM HUMULUS LUPULUS.
PHYTOCHEMISTRY (1997) 46 (4) pp. 683-687 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
KITASATO INST RES CENT BIOL FUNCTION TOKYO 108 JAPAN INHIBITORS OF NITRIC OXIDE PRODUCTION FROM HOPS (HUMULUS LUPULUS L.).
ZHAO,F: NOZAWA,H: DAIKONNYA,A: KONDO,K: KITANAKA,S: BIOL PHARM BULL (2003) 26 (1) pp. 61-65 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
KIRIN BREWERY CO LTD CENTRAL LAB KEV TECHNOLOGY KANAGAWA 2360004 JAPAN PRENYLFLAVONOIDS AND PHLOROGLUCINOL DERIVATIVES FROM HOPS (HUMULUS LUPULUS).
ZHAO,F: WATANABE,Y: NOZAWA,H: DAIKONNYA,A: KONDO,K: KITANAKA,S: J NAT PROD (2005) 68 (1) pp. 43-49 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
KIRIN BREWERY CO LTD CENT LAB KEY TECHNOL KANAGAWA 2360004 JAPAN ANTIPROLIFERATIVE AND CYTOTOXIC EFFECTS OF PRENYLATED FLAVONOIDS FROM HOPS (HUMULUS LUPULUS) IN HUMAN CANCER CELL LINES.
MIRANDA,CL: STEVENS,JF: HELMRICH,A: HENDERSON,MC: RODRIGUEZ,RJ: YANG,YH: DEINZER,ML: BARNES,DW: BUHLER,DR: FOOD CHEM TOXICOL (1999) 37 (4) pp. 271-285 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
OREGON STATE UNIV DEPT ENVIRON MOL TOXICOL COLL PHARM CORVALLIS OR 97331 USA LITERATURE CITED
IDENTIFICATION OF A POTENT PHYTOESTROGEN IN HOPS (HUMULUS LUPULUS L.) AND BEER.
MILLIGAN,SR: KALITA,JC: HEYERICK,A: RONG,H: DE COOMAN,L: DE KEUKELEIRE,D: J CLIN ENDOCRINOL METAB (1999) 83 (6) pp. 2249-2252 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
KING'S COLL PHYSIOL DIV SCH BIOMED SCI LONDON ENGLAND FATE OF XANTHOHUMOL AND RELATED PRENYLFLAVONOIDS FROM HOPS TO BEER.
STEVENS,JF: TAYLOR,AW: CLAWSON,JE: DEINZER,ML: J AGR FOOD CHEM (1999) 47 (6) pp. 2421-2428 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
OREGON STATE UNIV DEPT CHEM CORVALLIS OR 97331 USA ANTIOXIDANT AND PROOXIDANT ACTIONS OF PRENYLATED AND NONPRENYLATED CHALCONES AND FLAVANONES IN VITRO.
MIRANDA,CL: STEVENS,JF: IVANOV,V: MC CALL,M: FREI,B: DEINZER,ML: BUHLER,DR: J AGR FOOD CHEM (2000) 48 pp. 3876-3884 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
OREGON STATE UNIV DEPT CHEM CORVALLIS OR USA IN VITRO INHIBITION OF HUMAN P450 ENZYMES BY PRENYLATED FLAVONOIDS FROM HOPS, HUMULUS LUPULUS.
HENDERSON,MC: MIRANDA,CL: STEVENS,JF: DEINZER,ML: BUHLER,DR: XENOBIOTICA (2000) 30 (3) pp. 235-251 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
OREGON STATE UNIV DEP ENVIRONMENTAL MOL TOXICOL CHEM CORVALLSI OR 97331 USA THE OESTROGENIC ACTIVITY OF HOPS (HUMULUS LUPULUS L.) REVISITED.
KEUKELEIRE,D: MILLIGAN,D: COOMAN,D: HEYERICK,L: PHARM PHARMACOL LETT (1997) 7 (2/3) pp. 83-86 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
UNIV GENT FAC PHARM SCIENCES LAB PHARMACO PHYTOCHEM GENT BELGIUM INFLUENCE OF PRENYLATED AND NON-PRENYLATED FLAVONOIDS ON LIVER MICROSOMAL LIPID PEROXIDATION AND OXIDATIVE INJURY IN RAT HEPATOCYTES.
RODRIGUEZ,RJ: MIRANDA,CL: STEVENS,JF: DEINZER,ML: BUHLER,DR: FOOD CHEM TOXICOL (2001) 39 (5) pp. 437-445 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
OREGON STATE UNIV DEPT PHARMACEUTICAL SCI CORVALLIS OR USA LITERATURE CITED
APOPTOSIS AND CYTOTOXICITY TO HL-60 BY TWO BONE RESORPTION INHIBITORS, HUMULONE AND XANTHOHUMOL.
GAKUJUTSU KIYO KOCHI KOGYO KOTO SENMON GAKKO (2000) 45 pp. 39-44 INFORMATION CODED FROM AN ABSTRACT. * CHEMICAL ABSTRACTS 134 51165 A KOCHI NATION COLL TECHNOL DEPT MATERI SCI ENGINEE JAPAN IDENTIFICATION AND BIOLOGICAL ACTIVITY OF MICROBIAL METABOLITES OF XANTHOHUMOL.
CHEM PHARM BULL (2003) 51 (11) pp. 1237-1240 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
UNIV MISSISSIPPI NAT CENT DEV NAT PROD RES INST PHARM SCI UNIVERSITY MS 38677 USA ANTIVIRAL ACTIVITY OF HOP CONSTITUENTS AGAINST A SERIES OF DNA AND RNA VIRUSES.
BUCKWOLD,VE: WILSON,RJH: NALCA,A: BEER,BB: VOSS,TG: TURPIN,JA: BUCKHEIT III,RW: WEI,J: WENZEL-MATHERS,M: WALTON,EM: SMITH,RJ: PALLANSCH,M: WARD,P: WELLS,J: CHUVALA,L: SLOANE,S: PAULMAN,R: RUSSELL,J: HARTMAN,T: PTAK,R: ANTIVIRAL RES (2004) 61 (1) pp. 57-62 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
SOUTHERN RES INST INFECT DIS RES DEPT FREDERICK MD 21701 USA INHIBITION OF STREPTOCOCCUS MUTANS AND OTHER ORAL STREPTOCOCCI BY HOP (HUMULUS LUPULUS L.) CONSTITUENTS.
BHATTACHARYA,S: VIRANI,S: ZAVRO,M: HAAS,GJ: ECON BOT (2003) 57 (1) pp. 118-125 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
FAIRLEIGH DICKINSON UNIV SCH NAT SCI TEANECK NJ 07666 USA IN VITRO PHASE II METABOLISM OF XANTHOHUMOL BY HUMAN UDP-GLUCURONOSYLTRANSFERASES AND SULFOTRANSFERASES.
RUEFER,CE: GERHAUSER,C: FRANK,N: BECKER,H: KULLING,SE: MOL NUTR FOOD RES (2005) 49 pp. 851-856 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
FED RES CEN NUTR FOOD INST NUTR PHYSIOL KARLSRUHE GERMANY XANTHOHUMOL INDUCES APOPTOSIS IN CULTURED 40-16 HUMAN COLON CANCER CELLS BY ACTIVATION OF THE DEATH RECEPTOR- AND MITOCHONDRIAL PATHWAY.
MOL NUTR FOOD RES (2005) 49 pp. 837-843 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
GERMAN CAN RES CEN DIV TOX CANCER RISK FACTORS HEIDELBERG GERMANY LITERATURE CITED
XANTHOHUMOL KILLS B-CHRONIC LYMPHOCYTIC LEUKEMIA CELLS BY AN APOPTOTIC MECHANISM.
LUST,S: VANHOECKE,B: JANSSENS,A: PHILIPPE,J: BRACKE,M: OFFNER,F: MOL NUTR FOOD RES (2005) 49 pp. 844-850 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
GHENT UNIV HOSP DEPT HEMATOL GENT BELGIUM XANTHOHUMOL DOES NOT AFFECT THE COMPOSITION OF RAT INTESTINAL MICROBIOTA.
HANSKE,L: HUSSONG,R: GERHAUSER,C: BLAUT,M: BRAUNE,A: MOL NUTR FOOD RES (2005) 49 pp. 868-873 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
GERMAN INST HUM NUTR POTSDAM DEPT GESTROINTEST MICROBIOL NUTHETAL GERMANY A SAFETY STUDY OF ORAL XANTHOHUMOL ADMINSTRATION AND ITS INFLUENCE ON FERTILITY IN SPRAGUE DAWLEY RATS.
HUSSONG,R: FRANK,N: ITTRICH,C: OWEN,R: BECKER,H: GERHAUSER,C: MOL NUTR FOOD RES (2005) 49 pp. 861-867 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
DEUTSCHES KREBSCHUNGSZENTRUM DIV TOXICOL CAN RISK FACTORS HEIDELBERG GERMANY XANTHOHUMOL METABOLITES IN FAECES OF RATS.
NOOKANDEH,A: FRANK,N: STEINER,F: ELLINGER,R: SCHNEIDER,B: GERHAUSER,C: BECKER,H: PHYTOCHEMISTRY (2004) 65 (5) pp. 561-570 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
UNIV SAARLANDS PHARMAKOG & ANAL PHYTOCHEM SAARBRUCKEN D-6600 GERMANY XANTHOHUMOL STIMULATES IODIDE UPTAKE IN RAT THYROID-DERIVED FRTL-5 CELLS.
MOL NUTR FOOD RES (2005) 49 pp. 832-836 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
CHARITE UNIV BERLIN INST EXPER ENDOKRINOL FORSCHUNGSZENTRUM ENFORCE BERLIN D-10117 GERMANY IN VITRO GLUCURONIDATION OF XANTHOHUMOL, A FLAVONOID IN HOPS AND BEER, BY RAT AND HUMAN LIVER MICROSOMES FEBS LETT (2001) 491 pp. 252-256 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
OREGON STATE UNIV DEPT ENVIRONMENTAL MOLECULAR TOXICOLOGY CORVALLIS OR 97331 USA LITERATURE CITED
INFLUENCE OF PRENYLATED FLAVONOIDS ON LIVER MICROSOMAL LIPID PEROXIDATION AND OXIDATIVE INJURY IN RAT HEPATOCYTES RODRIGUEZ,RF: MIRANDA,CL: STEVENS,JF: DEINZER,ML: BUHLER,DR: FOOD CHEM TOXICOL (2001) 39 pp. 437-445 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
OREGON STATE UNIV DEPT PHARM SCI CORVALLIS OR USA IN VITRO BIOTRANSFORMATION OF XANTHOHUMOL, A FLAVONOID FROM HOPS (HUMULUS LUPULUS), BY RAT LIVER MICROSOMES.
YILMAZER,M: STEVENS,JF: DEINZER,ML: BUHLER,DR: DRUG METAB DISPOS (2001) 29 (3) pp. 223-231 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
OREGON STATE UNIV DEPT ENVIRON MOL TOXICOL CORVALLIS OR USA INHIBITION OF PEROXYNITRITE-MEDIATED LDL OXIDATION BY PRENYLATED FLAVONOIDS: THE A,B-UNSATURATED KETO FUNCTIONALITY OF 2'-HYDROXYCHALCONES AS A NOVEL ANTIOXIDANT PHARMACOPHORE.
STEVENS,JF: MIRANDA,CL: FREI,B: BUHLER,D: CHEM. RES. TOXICOL (2003) 16 pp. 1277-1286 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
OREGON STATE UNIV DEPT CHEM CORVALLIS OREGON 97331-7301 USA PRENYLATED CHALCONES AND FLAVANONES AS INDUCERS OF QUINONE REDUCTASE IN MOUSE HEPA 1C1C7 CELLS.
MIRANDA,CL: APONSO,GLM: STEVENS,JF: DEINZER,ML: BUHLER,DR: CANCER LETT (2000) 149 pp. 21-29 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
OREGON STATE UNIV DEPT ENVIRON MOL TOXICOLOGY CORVALLIS OREGON 97331 USA THE ENDOCRINE ACTIVITIES OF 8-PRENYLNARINGENIN AND RELATED HOP (HUMULUS LUPULUS L.) FLAVONOIDS.
MILLIGAN,SR: KALITA,JC: POCOCK,V: VAN DE KAUTER,V: STEVENS,JF: DEINZER,ML: RONG,H: DE KEUKELEIRE,D: J CLIN ENDOCRINOL METAB (2000) 85 (12) pp. 4912-4915 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
OREGON STATE UNIV DEPT CHEM CORVALLIS OREGON 97331 USA PRENYLFLAVONOIDS FROM HOPS INHIBIT THE METABOLIC ACTIVATION OF THE CARCINOGENIC HETEROCYCLIC AMINE 2-AMINO-3-METHYLIMIDAZO[4,5-F]QUINOLINE, MEDIATED BY CDNA-EXPRESSED HUMAN CYP1A2.
MIRANDA,CL: YANG,YH,: HENDERSON,MC: STEVENS,JF: SANTANA-RIOS,G: DEINZER,ML: BUHLER,DR: DRUG METAB DISPOS (2000) 28 (11) pp. 1297-1302 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
OREGON STATE UNIV DEPT CHEM CORVALLIS OREGON 97331-7301 USA LITERATURE CITED
ACTIVATION OF PROESTROGENS FROM HOPS (HUMULUS LUPULUS L.) BY INTESTINAL MICROBIOTA; CONVERSION OF ISOXANTHOHUMOL INTO 8-PRENYLNARINGENIN.
POSSEMIERS,S: HEYERICK,A: ROBBINS,V: DE KEUKELEIRE,D: VERSTRAETE,W: J AGR FOOD CHEM (2005) 53 pp. 6281-6288 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
GENT UNIV LAB MICROBIAL ECOLOGY TECH FAC BIOSCI ENG GENT B-9000 BELGIUM METABOLISM OF XANTHOHUMOL AND ISOXANTHOHUMOL,PRENYLATED FLAVONOIDS FROM HOPS (HUMULUS LUPULUS L.), BY HUMAN LIVER MICROSOME.
NIKOLIC,D: LI,YM: CHADWICK,LR: PAULI,GF: VAN BREEMEN,RB: J MASS SPECTROM (2005) 40 pp. 289-299 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
UNIV ILL CHGO DEPT MED CHEM PHARMACOG COLL PHARM CHICAGO IL 60612-7231 USA XANTHOHUMOL ISOLATED FROM HUMULUS LUPULUS INHIBITS MENADIONE-INDUCED DNA DAMAGE THROUGH INDUCTION OF QUINONE REDUCTASE DIETZ,BR: KANG,YH: LIU,GW: EGGLER,AL: YAO,P: CHADWICK,LR: PAULI,GF: FARNSWORTH,NR: MESECAR,AD: VAN BREEMEN,RB: BOLTON,JL: CHEM RES TOXICOL (2005) 18 (8) pp. 1296-1305 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
COLLEGE OF PHARMACY, UNIVERSITY OF ILLINOIS AT CHICAGO DEPARTMENT OF MEDICINAL CHEMISTRY AND PHARMACOGNOSY UIC/NIH CENTER FOR BOTANICAL AND DIETARY SUPPLEMENTS CHICAGO ILLINOIS 60612 USA XANTHOHUMOL, A PRENYLFLAVONOID DERIVED FROM HOPS INDUCES APOPTOSIS AND INHIBITS NF-KAPPA-B ACTIVATION IN PROSTATE EPITHELIAL CELLS COLGATE,EC: MIRANDA,CL: STEVENS,JF: BRAY,TM: HO,E: CANCER LETT (2007) 246 (2007) pp. 201-209 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
OREGON STATE UNIVERSITY DEPARTMENT OF NUTRITION AND EXERCISE SCIENCES CORVALLIS OREGON USA MODULATION OF BREAST CANCER CELL SURVIVAL BY AROMATASE INHIBITION HOP (HUMULUS IUPULUS L.) FLAVONOIDS MONTEIRO,R: FARIA,A: AZEVEDO,I: CALHAU,C: J STEROID BIOCHEM MOL BIOL (2007) 105 pp. 124-130 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
UNIV PORTO DEPT BIOCHEM FACULTY MEDICINE PORTO 4200-319 PORTUGAL SYNTHESIS OF DEMETHYLXANTHOHUMOL, A NEW POTENT APOPTOSIS-INDUCING AGENT FROM HOPS.
DILLER,RA: RIEPL,HM: FRIAS,C: HENZE,G: PROKOP,A: CHEMISTRY & BIODIVERSITY (2005) 2 pp. 1331-1337 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
TECHNICAL UNIV MUNICH INST TECHNOL BIOGENIC RES MUNICH D-94315 GERMANY LITERATURE CITED
IN VITRO ANTIPLASMODIAL ACTIVITY OF PRENYLATED CHALCONE DERIVATIVES OF HOPS (HUMULUS LUPULUS) AND THEIR INTRACTION WITH HAEMIN.
FROLICH,S: SCHUBERT.C: BIENZLE,U: JENETT-SIEMS,K: J ANTIMICROB CHEMOTHER (2005) 55 pp. 883-887 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
FREIE UNIV BERLIN INST PHARM BERLIN D-141195 GERMANY XANTHOHUMOL, A NOVEL ANTI-HIV-1 AGENT PURIFIED FROM HOPS HUMULUS LUPULUS.
ANTIVIRAL RES (2004) 64 pp. 189-194 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
CHIN ACAD SCI LAB MOLE IMMUNOPHARMACOL KUNMING INST ZOOLOGY KUNMING 650223 CHINA BINDING OF THE HOP (HUMULUS LUPULUS L.) CHALCONE XANTHOHUMOL TO CYTOSOLIC PROTEINS IN CACO-2 INTESTINAL EPITHELIAL CELLS.
PANG,Y: NIKOLIC,D: ZHU,DW: CHADWICK,LR: PAULI,GF: FARNSWORTH,NR: VAN BREEMEN,RB: MOL NUT FOOD RES (2007) 51 pp. 872-879 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
UNIVERSITY OF ILLINOIS AT cHICAGO DEPT MED CHEM & PHARMACOGNOSY COLLEGE OF PHARMACY CHICAGO IL 60612 USA XANTHOHUMOL ISOLATED FROM HUMULUS LUPULUS INHIBITS MENADIONE-INDUCED DNA DAMAGE THROUGH INDUCTION OF QUINONE REDUCTASE DIETZ,BM; KANG,YH; LIU, GW; EGGLER, AL; YAO,P; CHADWICK,LR; PAULI,GF; FARNSWORTH,NR; MESECAR,AD; VAN BREEMEN,RB; BOLTON,JL CHEM RES TOXICOL (2005) 18 (8) pp. 1296-1305 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
UNIV ILLINOIS CHICAGO DEPT MED CHEM PHARMACOGNOSY COLL PHARM CHICAGO IL USA EFFECT OF HOP (HUMULUS LUPULUS L.) FLAVONOIDS ON AROMATASE (ESTROGEN SYNTHASE) ACTIVITY.
MONTEIRO,R: BECKER,H: AZEVEDO,I: CALHAU,C: J AGR FOOD CHEM (2006) 54 pp. 2938-2943 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
ANTICOCCIDIAL EFFECTS OF XANTHOHUMOL.
AVIAN DISEASES (2007) 51 pp. 21-26 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
ANIMAL PARASITIC DISEASES LAB U.S DEPT AGRI-AGRI RES SERVICE BELTSVILLE MD 20705 USA LITERATURE CITED
MECHANISMS OF THE ANTIANGIOGENIC ACTIVITY BY THE HOP FLANONOID XANTHOHUMOL: NF-KB AND AKT AS TARGETS.
ALBINI,A: DELL-EVA,R: VENE,R: FERRARI,N: BUHLER,DR: NOONAN,DM: FASSINA,G: FASEB J EXPRESS ARTICLE 10.1096/FJ.05.5128.FJE (2005) 2005 pp. 1-21 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
MOLE ONCOL LAB ISTITUO NAZIONALE PER LA RICERCA SUL CANCRO GENOA ITALY ANTIINVASIVE EFFECT OF XANTHOHUMOL, A PRENYLATED CHALCONE PRESENT IN HOPS (HUMULUS LUPULUS L.) AND BEER.
VANHOECKE,B: DERYCKE,L: VAN MARCK,V: DEPYPERE,H: DE KEUKELEIRE,D: BRACKE,M: INT J CANCER (2005) 117 pp. 889-895 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
GHENT UNIV HOSP DEPT GYNECOLOGY GHENT B-9000 BELGIUM EFFECT OF XANTHOHUMOL AND ISOANTHOHUMOL ON 3T3-L1 CELL APOPTOSIS AND ADIPOGENESIS.
YANG,JY: DELLA-FERA,MA: RAYALAM,S: BAILE,CA: APOPTOSIS (2007) 12 pp. 1953-1963 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
UNIV GEORGIA DEPT ANIMAL DAIRY SCI ATHENS GA 30602-2771 USA IDENTIFICATION OF HUMAN HEPATIC CYTOCHROME P450 ENZYMES INVOLVED IN THE METABOLISM OF 8-PRENYLNARINGENIN AND ISOXANTHOHUMOL FROM HOPS (HUMULUS LUPULUS L.) GUO,J; NIKOLIC,D; CHADWICK,LR; PAULI,GF; VAN BREEMEN,RB DRUG METABOL DISPOSIT (2006) 34 (7) pp. 1152-1159 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
UNIV ILLINOIS CHICAGO DEPT MED CHEM PHARMACOGNOSY COLL PHARM CHIGAGO IL 60612 USA SCREENING METHOD FOR THE DISCOVERY OF POTENTIAL CANCER CHEMOPREVENTION AGENTS BASED ON MASS SPECTROMETRIC DETECTION OF ALKYLATED KEAP1 LIU,G; EGGLER,A; DIETZ,B; MESECAR,A; BOLTON,JA; PEZZUTO,JM; VAN BREEMEN,RB ANAL CHEM (2005) 77 (19) pp. 6407-6414 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
UNIV ILLINOIS CHICAGO DEPT MED CHEM PHARMACOGNOSY COLL PHARM CHICAGO IL 60612 USA XANTHOHUMOL, THE CHALCONE FROM BEER HOPS (HUMULUS LUPULUS L.), IS THE LIGAND FOR FARNESOID X RECEPTOR AND AMELIORATES LIPID AND GLUCOSE METABOLISM IN KK-AY MICE BIOCHEM BIOPHYS RES COMMUN (2005) 336 (3) pp. 754-761 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
KIRIN BREWERY CO. LTD. R & D LABORATORY FUNCTIONAL FOOD DIVISION GUNMA 370-1295 JAPAN LITERATURE CITED
REGULATION OF OSTEOBLASTIC PHENOTYPE AND GENE EXPRESSION BY HOP-DERIVED PHYTOESTROGENS EFFENBERGER,KE; JOHNSEN,SA; MONROE,DG; SPELSBERG,TC; WESTENDORF,JJ J STEROID BIOCHEM MOL BIOL (2005) 96 (5) pp. 387-399 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
UNIV HAMBURG INSTITUTE FOR EXPERIMENTAL AND CLINICAL PHARMACOLOGY AND TOXICOLOGY UNIV HOSPITAL EPPENDORF HAMBURG 22527 GERMANY INFLUENCE OF XANTHOHUMOL ON THE BINDING BEHAVIOR OF GABA-A RECEPTORS AND THEIR LATERAL MOTILITY AT HIPPOCAMPAL NEURONS PLANTA MED (2006) 72 (7) pp. 656-658 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
UNIV MARBURG DEPT PHARM BIOLOGY MARBURG GERMANY TREATMENT OF PC-3 AND DU145 PROSTATE CANCER CELLS BY PRENYLFLAVONOIDS FROM HOP (HUMULUS LUPULUS L.) INDUCES A CASPASE-INDEPENDENT FORM OF CELL DEATH DELMULLE,L: VANDEN BERGHE,T: DE KEUKELEIRE,D: VANDENABEELE,P PHYTOTHER RES 22 (2) pp. 197-203 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
UNIV GHENT FACULTY OF PHARMACEUTICAL SCIENCES LABORATORY OF PHARMACOGNOSY AND PHYTOCHEMISTRY GHENT B-9000 BELGIUM CANCER CHEMOPREVENTIVE ACTIVITY OF XANTHOHUMOL, A NATURAL PRODUCT DERIVED FROM HOP GERHAUSER,C: ALT,A: HEISS,E: GAMAL-ELDEEN,A: KLIMO,K: KNAUFT,J: NEUMANN,I: SHERF,HR: FRANK,N: BARTSCH,H: BECKER,H MOLECULAR CANCER THERAPEUTICS (2002) 1 (11) pp. 959-969 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
DEUTSCHES KREBSFORSCHUNGZENTRUM HEIDELBERG GERMANY PROTECTIVE EFFECTS OF XANTHOHUMOL AGAINST THE GENOTOXICITY OF BENZO(A)PYRENE (BAP), 2-AMINO-3-METHYLIMIDAZO[4,5-F]QUINOLINE (IQ) AND TERT-BUTYL HYDROPEROXIDE (T-BOOH) IN HEP G2 HUMAN HEPATOMA CELLS MUTAT RES (2007) 632 pp. 1-8 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
ANTI-PROLIFERATIVE PROPERTIES OF PHENYLATED FLAVONOIDS FROM HOPS (HUMULUS LUPULUS L.) IN HUMAN PROSTATE CANCER CELL LINES DELMULLE,L: BELLAHCENE,A: DHOOGE,W: COMHAIRE,F: ROELENS,F: HUVAERE,K: HEYERICK,A: CASTRONOVO,V: DEKEUKELEIRE,D PHYTOMEDICINE (2006) 13 pp. 732-734 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
GHENT UNIV FAC PHARM SCI GHENT B-9000 BELGIUM LITERATURE CITED
IDENTIFICATION OF HUMAN HEPATIC CYTOCHROME P450 ENZYMES INVOLVED IN THE METABOLISM OF 8-PRENYLNARINGENIN AND ISOXANTHOHUMOL FROM HOPS (HUMULUS LUPULUS L.).
GUO,J: NIKOLIC,D: CHADWICK,LR: PAULI,GF: VAN BREEMEN, BR: DRUG METABOLISM DISPOSITION (2006) 34 (7) pp. 1152-1159 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
UNIV ILL CHICAGO DEPT MED CHEM PHARMACOL COLL PHARMACY CHICAGO ILLINOIS 60612 USA INFLUENCE OF XANTHOHUMOL ON THE BINDING BEHAVIOR OF GABAA RECEPTORS AND THEIR LAATERAL MOBILITY AT HIPPOCAMPAL NEURONS.
PLANTA MED (2006) 72 pp. 656-658 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
UNIV MARBURG DEPT PHARMACEUT BIOL MARBURG GERMANY ANTIGENOTOXIC EFFECT OF XANTHOHUMOL IN RAT LIVER SLICES.
TOXICOLOGY (2008) 22 (2) pp. 318-327 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
UNIV GRONINGEN DEPT PHARMACOKINETICS DRUG DELIVERY UNIV CENT PHARMACY GRONINGEN NETHERLANDS ANTIMUTAGENICITY OF HOPS (HUMULUS LUPULUS L.): BIOASSAY-DIRECTED FRACTIONATION AND ISOLATION OF XANTHOHUMOL KAC,J: PLAZAR,J: MLINARIC,A: ZEGURA,B: LAH,TT: FILIPIC,M PHYTOMEDICINE (2008) 15 (3) pp. 216-220 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
UNIV LJUBLJANA DEPT PHARMACEUTICAL BIOL FAC PHARMACY LJUBLJANA SLOVENIA INHIBITION OF ADENOSINE 3',5'-CYCLIC MONOPHOSPHATE PHOSPHODIESTERASE BY COMPONENTS OF SOPHORA FLAVESCENS AITON.
OHMOTO,T: AIKAWA,R: NIKAIDO,T: SANKAWA,U: WU,LJ: UENO,A: FUKUSHIMA,S: CHEM PHARM BULL (1986) 34 (5) pp. 2094-2099 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
TOHO UNIV SCH PHARMACEUT SCI CHIBA 274 JAPAN

Source: http://www.napralert.org/NapralertReport_Xanthohumol_exper.pdf